236 related articles for article (PubMed ID: 26436478)
1. Defining the risk threshold for risk reducing salpingo-oophorectomy for ovarian cancer prevention in low risk postmenopausal women.
Manchanda R; Legood R; Pearce L; Menon U
Gynecol Oncol; 2015 Dec; 139(3):487-94. PubMed ID: 26436478
[TBL] [Abstract][Full Text] [Related]
2. Specifying the ovarian cancer risk threshold of 'premenopausal risk-reducing salpingo-oophorectomy' for ovarian cancer prevention: a cost-effectiveness analysis.
Manchanda R; Legood R; Antoniou AC; Gordeev VS; Menon U
J Med Genet; 2016 Sep; 53(9):591-9. PubMed ID: 27354448
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer.
Wei X; Sun L; Slade E; Fierheller CT; Oxley S; Kalra A; Sia J; Sideris M; McCluggage WG; Bromham N; Dworzynski K; Rosenthal AN; Brentnall A; Duffy S; Evans DG; Yang L; Legood R; Manchanda R
JAMA Netw Open; 2024 Feb; 7(2):e2355324. PubMed ID: 38334999
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study.
Mai PL; Piedmonte M; Han PK; Moser RP; Walker JL; Rodriguez G; Boggess J; Rutherford TJ; Zivanovic O; Cohn DE; Thigpen JT; Wenham RM; Friedlander ML; Hamilton CA; Bakkum-Gamez J; Olawaiye AB; Hensley ML; Greene MH; Huang HQ; Wenzel L
Gynecol Oncol; 2017 Apr; 145(1):122-129. PubMed ID: 28190649
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
Yamauchi H; Nakagawa C; Kobayashi M; Kobayashi Y; Mano T; Nakamura S; Arai M
Breast Cancer; 2018 Mar; 25(2):141-150. PubMed ID: 29019095
[TBL] [Abstract][Full Text] [Related]
6. Setting the Threshold for Surgical Prevention in Women at Increased Risk of Ovarian Cancer.
Manchanda R; Menon U
Int J Gynecol Cancer; 2018 Jan; 28(1):34-42. PubMed ID: 29252925
[TBL] [Abstract][Full Text] [Related]
7. Factors influencing uptake and timing of risk reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis.
Manchanda R; Burnell M; Abdelraheim A; Johnson M; Sharma A; Benjamin E; Brunell C; Saridogan E; Gessler S; Oram D; Side L; Rosenthal AN; Jacobs I; Menon U
BJOG; 2012 Apr; 119(5):527-36. PubMed ID: 22260402
[TBL] [Abstract][Full Text] [Related]
8. Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous/serous-like uterine cancers in BRCA1 mutation carriers.
Havrilesky LJ; Moss HA; Chino J; Myers ER; Kauff ND
Gynecol Oncol; 2017 Jun; 145(3):549-554. PubMed ID: 28390820
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of testing for breast cancer susceptibility genes.
Holland ML; Huston A; Noyes K
Value Health; 2009; 12(2):207-16. PubMed ID: 18647256
[TBL] [Abstract][Full Text] [Related]
10. Bone mineral density and fractures after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer.
Fakkert IE; Abma EM; Westrik IG; Lefrandt JD; Wolffenbuttel BH; Oosterwijk JC; Slart RH; van der Veer E; de Bock GH; Mourits MJ
Eur J Cancer; 2015 Feb; 51(3):400-8. PubMed ID: 25532426
[TBL] [Abstract][Full Text] [Related]
11. The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy.
van der Aa JE; Hoogendam JP; Butter ES; Ausems MG; Verheijen RH; Zweemer RP
Fam Cancer; 2015 Dec; 14(4):539-44. PubMed ID: 26264902
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry.
Manchanda R; Patel S; Antoniou AC; Levy-Lahad E; Turnbull C; Evans DG; Hopper JL; Macinnis RJ; Menon U; Jacobs I; Legood R
Am J Obstet Gynecol; 2017 Nov; 217(5):578.e1-578.e12. PubMed ID: 28690137
[TBL] [Abstract][Full Text] [Related]
13. Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study.
Gaba F; Blyuss O; Chandrasekaran D; Osman M; Goyal S; Gan C; Izatt L; Tripathi V; Esteban I; McNicol L; Ragupathy K; Crawford R; Evans DG; Legood R; Menon U; Manchanda R
BJOG; 2021 Mar; 128(4):714-726. PubMed ID: 32803845
[TBL] [Abstract][Full Text] [Related]
14. Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study.
Harmsen MG; Arts-de Jong M; Hoogerbrugge N; Maas AH; Prins JB; Bulten J; Teerenstra S; Adang EM; Piek JM; van Doorn HC; van Beurden M; Mourits MJ; Zweemer RP; Gaarenstroom KN; Slangen BF; Vos MC; van Lonkhuijzen LR; Massuger LF; Hermens RP; de Hullu JA
BMC Cancer; 2015 Aug; 15():593. PubMed ID: 26286255
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers.
Kwon JS; Tinker A; Pansegrau G; McAlpine J; Housty M; McCullum M; Gilks CB
Obstet Gynecol; 2013 Jan; 121(1):14-24. PubMed ID: 23232752
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.
Manchanda R; Legood R; Burnell M; McGuire A; Raikou M; Loggenberg K; Wardle J; Sanderson S; Gessler S; Side L; Balogun N; Desai R; Kumar A; Dorkins H; Wallis Y; Chapman C; Taylor R; Jacobs C; Tomlinson I; Beller U; Menon U; Jacobs I
J Natl Cancer Inst; 2015 Jan; 107(1):380. PubMed ID: 25435542
[TBL] [Abstract][Full Text] [Related]
17. Osteoporosis risk and management in BRCA1 and BRCA2 carriers who undergo risk-reducing salpingo-oophorectomy.
Garcia C; Lyon L; Conell C; Littell RD; Powell CB
Gynecol Oncol; 2015 Sep; 138(3):723-6. PubMed ID: 26086567
[TBL] [Abstract][Full Text] [Related]
18. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients.
Grann VR; Panageas KS; Whang W; Antman KH; Neugut AI
J Clin Oncol; 1998 Mar; 16(3):979-85. PubMed ID: 9508180
[TBL] [Abstract][Full Text] [Related]
19. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.
Guzauskas GF; Garbett S; Zhou Z; Spencer SJ; Smith HS; Hao J; Hassen D; Snyder SR; Graves JA; Peterson JF; Williams MS; Veenstra DL
JAMA Netw Open; 2020 Oct; 3(10):e2022874. PubMed ID: 33119106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
